RK Asset Management LLC Buys 39 Shares of Regeneron Pharmaceuticals, Inc. $REGN

RK Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,602 shares of the biopharmaceutical company’s stock after purchasing an additional 39 shares during the period. Regeneron Pharmaceuticals comprises about 6.4% of RK Asset Management LLC’s investment portfolio, making the stock its 5th biggest holding. RK Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,616,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kingswood Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company’s stock worth $681,000 after purchasing an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its holdings in shares of Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 19 shares in the last quarter. Private Trust Co. NA boosted its position in shares of Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 19 shares during the period. Proficio Capital Partners LLC grew its holdings in shares of Regeneron Pharmaceuticals by 6.2% during the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 19 shares in the last quarter. Finally, Cove Private Wealth LLC raised its position in Regeneron Pharmaceuticals by 4.5% during the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 20 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Jefferies Financial Group upped their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price for the company. UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Finally, BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Up 6.7%

REGN opened at $599.94 on Thursday. The firm has a market cap of $63.59 billion, a P/E ratio of 15.12, a price-to-earnings-growth ratio of 1.79 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The business has a 50 day moving average price of $570.67 and a 200 day moving average price of $568.93. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,045.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the company posted $11.56 earnings per share. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.